Vaxcyte, Inc. (PCVX) Stock Forecast & Price Target
Price as of Nov 17, 2026 close · Analyst estimates retrieved Nov 15, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)
Revenue and earnings estimates published by analysts covering Vaxcyte, Inc. (PCVX), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Vaxcyte, Inc., the average estimate for 2030 earnings per share is $2.19; 9 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Vaxcyte, Inc. (PCVX) forecast — frequently asked questions
What is the analyst price target for Vaxcyte, Inc.?
Analysts covering Vaxcyte, Inc. (PCVX) have a consensus price target of $122.33, 105.9% above the current price of $59.40. Published targets range from $120.00 to $125.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Vaxcyte, Inc.'s earnings?
The average analyst estimate for Vaxcyte, Inc. (PCVX) earnings per share in 2030 is 2.19, with individual estimates between 2.19 and 2.19.
How much revenue is Vaxcyte, Inc. expected to make?
Analysts forecast Vaxcyte, Inc. (PCVX) revenue of $1.95B in 2030, based on 6 published estimates.
How many analysts cover PCVX?
9 analysts contribute estimates for Vaxcyte, Inc. (PCVX). Thin coverage makes an average less reliable.
Analyst forecasts for other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.